Tonix Pharmaceuticals added approximately 21 million Medicare Part D beneficiaries to TONMYA coverage through an agreement effective immediately. Total government and commercial coverage now reaches approximately 166 million individuals, a change the company expects to increase patient access to the treatment.

Key Highlights

  • The agreement with a pharmacy benefit manager covers TONMYA for Medicare Part D plan beneficiaries and takes effect immediately.
  • Medicare coverage for TONMYA now totals 32 million lives, or 58% of that population.
  • Government and commercial payer access reaches 53% of approximately 314 million U.S. lives.

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a Pharmaceuticals: Major company, has added approximately 21 million Medicare Part D beneficiaries to TONMYA coverage through an agreement effective immediately.

Pharmacy Benefit Agreement Takes Effect

The arrangement is with a pharmacy benefit manager and covers TONMYA for Medicare Part D plan beneficiaries. Coverage applies to TONMYA, which is indicated for treating fibromyalgia in adults, and begins immediately. Tonix said the agreement is its second major managed Medicare agreement for the treatment.

Company Expects Broader Patient Access

The company described commercial and managed Medicare coverage agreements as reflecting the treatment’s value to patients and payers.